Johnson & Johnson announced on Thursday that the first clinical trials on coronavirus vaccine candidates have begun in the United States and Belgium.
MODERN STARTS PHASE 3 OF THE VACCINE
“We are pleased to see these preclinical data, as they show that our SARS-CoV-2 vaccine candidate has elicited a strong response to antibodies and provided protection in a single dose,”; said Dr. Paul Stoffels, the company’s chief scientific officer. statement. “The results give us confidence as we advance vaccine development and high-end production in parallel, starting the Phase 1 / 2a trial in July with the intention of moving to the Phase 3 trial in September.”
|JNJ||JOHNSON & JOHNSON||146.54||-0.29||-0.20%|
The Johnson & Johnson trials will include a “significant representation” of color communities and the elderly who have been disproportionately affected by the virus, the company said.
Now the pharmaceutical giant has good news after falling profits in the second quarter. The company saw a slow demand for both cosmetics and medical devices, which affected its essence.
CLICK HERE TO READ MORE ABOUT FOX BUSINESS
Twenty coronavirus vaccines are currently being clinically tested, according to research by the Milken Institute. Modern, based in the United States, is one of the most advanced companies in vaccine development.
COMPLETE FOX BUSINESS ON THE ROAD, CLICK HERE